HHealthcare Read More Trump deals with Lilly, Novo Nordisk could broaden obesity drug accessNovember 7, 2025 US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC…
HHealthcare Read More Trump strikes deal with Eli Lilly, Novo NordiskNovember 6, 2025 Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg |…
HHealthcare Read More Metsera calls Novo Nordisk’s new bid superior to Pfizer offerNovember 4, 2025 The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
HHealthcare Read More Pfizer files second lawsuit against Novo Nordisk, MetseraNovember 3, 2025 A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California,…
HHealthcare Read More Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidNovember 1, 2025 Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer said on Friday it had filed a lawsuit against Metsera and Novo…
HHealthcare Read More We’re raising our Eli Lilly price target — what a difference a quarter makesOctober 30, 2025 Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its…
HHealthcare Read More Eli Lilly (LLY) earnings Q3 2025October 30, 2025 David Ricks, chief executive officer of Eli Lilly & Co., during a news conference at Generation Park in…
HHealthcare Read More Eli Lilly, Merck, Gilead and AbbVie earnings previewOctober 28, 2025 The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday,…
HHealthcare Read More Novo Nordisk chair and directors quit after boardroom riftOctober 21, 2025 The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
MMarkets Read More Stock market today: Live updatesOctober 16, 2025 Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October…
HHealthcare Read More Novo Nordisk and Omeros announce asset purchase and licenseOctober 15, 2025 Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…
MMarkets Read More Stock market today: Live updatesOctober 9, 2025 Traders work on the floor of the New York Stock Exchange. NYSE The S&P 500 and Nasdaq Composite…